Angiotensin II (Ang II) regulates cerebral blood flow by stimulating cerebral vasoconstriction via AT 1receptors. In adult spontaneously hypertensive rats (SHR), the cerebrovascular autoregulatory curve is shifted to the right, in the direction of higher blood pressures, an indication of excessive cerebrovascular vasoconstriction. A restricted capacity to dilate cerebral blood vessels may be responsible for the enhanced vulnerability to cerebrovascular ischaemia during hypertension. We found that chronic treatment with the AT 1 -receptor antagonist, candesartan, (0.5 mg/kg/day for 14 days, via osmotic minipumps implanted in the subcutaneous tissue) blocked Ang II binding to AT 1 -receptors in cerebral blood vessels and in brain areas involved in the regulation of cerebrovascular flow, and increased the ratio of lumen-wall area in the middle cerebral artery. Candesartan treatment normalised the lower part of the autoregulatory curve in SHR, and markedly decreased cerebral ischaemia as a consequence of middle cerebral artery occlusion with reperfusion. Protection from ischaemia is related to arterial remodelling, enhanced compensatory vasodilatation in the peripheral area of ischaemia, decreased reduction in cerebral blood flow following the occlusion of a major cerebral blood vessel, and protection from injury in the periphery of the lesion. Our results indicate that pre-treatment with AT 1 -antagonists such as candesartan could be of benefit in the prevention and treatment of brain ischaemia.
Introduction
In addition to its role in the regulation of blood pressure (BP) and fluid metabolism, Angiotensin II (Ang II) participates in the modulation of cerebrovascular flow. Ang II receptors and angiotensin-converting enzyme (ACE) are present in cerebral microvessels and large cerebral arteries. [1] [2] [3] [4] The brain autoregulates the levels of cerebral blood flow within normal limits by compensating alterations in the calibre of large and of resistance cerebral vessels in response to changes in systemic BP. 5 Resistance arteries have a higher potential vasodilatory capacity during decreases in BP, and a lower vasoconstricting capacity during increases in BP. 6, 7 Sustained systemic hypertension produces alterations in the growth and the structure of cerebral arteries, with increased vasoconstriction and a lower capacity to dilate.This shifts the cerebrovascular autoregulation towards higher BPs, decreasing the cerebrovascular capacity to compensate for a sudden reduction of blood flow such as that resulting from occlusion of a major cerebral artery. As a result, chronic hypertension is associated with a predisposition and vulnerability to ischaemia and stroke.
The participation of Ang II in the control of cerebrovascular flow is highlighted by the finding that blockade of Ang II formation by ACE inhibitors (ACE-I) inhibits the vascular tone maintained by locally-produced Ang II and protects against focal cerebral ischaemia in spontaneously hypertensive rats (SHR). [8] [9] [10] Acute administration of candesartan, a potent AT 1 -receptor antagonist, to SHR, shifts their cerebrovascular autoregulatory response to the left in a manner similar to that of ACE-I. 11 We investigated whether chronic administration of AT 1 -antagonists could protect hypertensive rats from the effects of cerebral ischaemia.
Methods

Animals
Groups of six adult, 10-week-old male SHR, weighing 270-306 g, and age-matched male Wistar-Kyoto (WKY) rats, weighing 280-320 g, were purchased from Taconic Farms, Germantown, New York, USA. The NIMH Animal Care and Use Committee approved all procedures. Osmotic minipumps containing candesartan (0.5 mg/kg/day for 14 days), or vehicle (0.1N Na 2 CO 3 ) were implanted subcutaneously the day after arrival at NIMH. 12 Arterial pressures in conscious rats were measured one day before treatment and on the last day of treatment by the tail-cuff method. 12
Quantitative autoradiography
Separate groups of six vehicle-treated and six candesartan-treated SHR were used for autoradiography studies. Animals were killed by decapitation, the brains immediately dissected and frozen in isopentane on dry ice, and kept frozen at -80°C until used. Sections (16 µm) were cut in a cryostat at -20°C. Consecutive sections were used for autoradiographic quantification as described. 13, 14 Quantitative autoradiography of Ang II AT 1 -and AT 2 -receptors in brain sections was performed by incubation with 0.5 x 10 -9 M 125 I-Sar 1 -Ang II (2200 Ci/mmol, iodinated at New England Nuclear, Boston, Massachusetts, USA), in the presence of selective AT 1 -(10 -6 M losartan, Dupont Merck, Wilmington, Dellaware USA) or AT 2 -(10 -7 M CGP 42112, Neosystems, Strasbourg, France) receptor ligands, respectively, to determine the amount of AT 1 -and AT 2 -receptors, 13, 14 and results were expressed in 'apparent' units, (fmol/mg protein), after correcting with standards. 13, 14 Sections were further stained with haematoxylin-eosin for histological analysis and structures were identified according to Paxinos and Watson. 15 Groups contained six animals each, measured individually.
Determination of the ratio of lumen-wall areas in the middle cerebral artery
Additional groups of six vehicle-treated and six candesartan-treated SHR were sacrificed by decapitation. Their brains were immediately dissected and frozen as described above, and horizontal 16 µmthick sections were cut at the level of the olfactory nerve. The sections were thaw-mounted to microscope slides and stained with haematoxylin-eosin. Images of the middle cerebral artery were identified at four consecutive sections per each individual animal, using an image scanner connected to a light microscope (KS 300 Imaging System, Carl Zeiss, Hallbergmoos, Germany). The wall and lumen areas of the middle cerebral artery were calculated with image analysis software (NIH Image, version 1.62). The ratio of lumen-wall area was calculated as the lumen area/arterial wall area. 16
Cerebral blood flow autoregulation
We studied the lower part of the cerebral blood flow (CBF) autoregulatory curve in SHR and normotensive WKY rats anaesthetised with ketamine (100 mg/Kg i.p.) and xylazine (10 mg/Kg i.p.) and ventilated via intra-tracheal intubation with 0.35% halothane in 70% nitrous oxide and 30% oxygen. Systemic BP was decreased by haemorrhage. 12, 17 BP was lowered at a rate of approximately 5 mmHg/minute. BP, CBF and blood gases were measured at baseline, immediately before heamorrhage, and at intervals over the BP range 50 to 20 mmHg. CBF was determined with a laser-Doppler flowmetry probe (BPM2,Vasamedics, Inc., St. Paul, MN, U.S.A.). 12 The rats were placed in a stereotaxic frame and a hole was drilled in the parietal bone, leaving the dura mater intact. The flowmetry probe was fixed in a position less than 1 mm from the exposed dural surface, avoiding the proximity of any large or medium size cerebral vessel.
Reversible middle cerebral artery occlusion
We performed reversible right middle cerebral artery occlusions in SHR with reperfusion after 2 hours of ischaemia, with an intra-luminal thread technique. 18 Rats were anaesthetised with 3.0% halothane and maintained with 1.0% halothane in 70% nitrous oxide and 30% oxygen via a ventilator with intra-tracheal intubation. We monitored CBF by laser-Doppler flowmetry at a point 1 mm posterior to the bregma and 3 mm lateral from the dorsal midline of the affected hemisphere, located at the periphery of the zone of ischaemia. Ventilation was adjusted to keep blood pH between 7.35 and 7.45, PaCO 2 between 32 and 40 mmHg, and PaO 2 between 130 and 180 mmHg.
Rectal temperature was maintained between 36.5 and 37.5°C with a heating pad.
Measurement of volume of injury
Ischaemia resulting from middle cerebral artery occlusion lasted 2 hours, and was followed by reperfusion. We determined the infarct volume 24 hours after ischaemia by the 2,3,5-triphenyltetrazolium chloride (TTC) method. 19 Cerebral oedema was measured by subtracting the volume of the non-affected hemisphere from the volume of the affected hemisphere, divided by the volume of the non-affected hemisphere. The TTC method is an established technique for the detection and quantification of experimental cerebral infarction in rats. 19 TTC, which is colourless in solution, is reduced by enzymes of functioning mitochondria to yield a deep red formazan. 19 Infarcted brain regions (and fibre tracts such as the corpus callosum) do not convert TTC, remaining unstained and appearing white. Ischaemic areas revealed by the TTC method correspond closely measured with other histological methods. 19 Quantification of the size of the infarct is performed with image scanning and computerised microdensitometry, after correction for brain swelling. 20
Statistical analysis
We assessed changes in Ang II receptor binding (Figures 1 and 2) , BP, vascular morphology, infarction volume, brain oedema (Table 1 ) and CBF (Figure 3 ) in treated and untreated rats using Student's t-test. We used two-way analysis of variance to calculate the effect of duration of treatment on the autoregulation curve (Figure 4 ). We used a one-way repeated measure analysis of variance to compare CBF within a group and to determine the lower limit of the cerebrovascular autoregulation curves (Figure 4 ). We performed post analysis for significance with the Tukey's multiple comparison test.
Results
Effects of drug treatment on blood pressure
Systolic BPs were measured in six rats from each group using a tail-cuff method. BPs were significantly higher in non-treated SHR compared with non-treated WKY rats (166±3.4 and 124±5 mmHg for vehicle-treated SHR and WKY, respectively, p<0.05). In SHR, systolic BPs were decreased by treatment with candesartan, 0.5 mg/kg/day. After 14 days of treatment, the BP in SHR was normalised and not significantly different from that of untreated WKY rats ( Table 1) .
Effects of candesartan on Ang II AT 1 -and AT 2 -receptor expression in brain areas and middle cerebral artery of spontaneously hypertensive rats
Treatment with candesartan, 0.5 mg/kg/day for 14 days, decreased AT 1 -receptor binding in the nucleus of the solitary tract (NTS) the paraventricular nucleus (PVN) and the subfornical organ (SFO) of SHR when compared with vehicle-treated SHR (Figure 1) . No difference was noted in AT 2 -receptor binding in the inferior olive of SHR after candesartan treatment (results not shown). The middle cerebral artery of SHR predominantly expressed binding to AT 1 -receptors; binding to AT 2 -receptors was only about 10% of the total binding (results not shown). In the middle cerebral artery, candesartan treatment, 0.5 mg/kg/day for 14 days, decreased AT 1 -receptor binding by 80% ( Figure 2) . The apparent number of AT 1receptors was 8±2 fmol/mg protein in vehicletreated SHR with vehicle and 1.5±0.5 fmol/mg protein in candesartan-treated SHR (p<0.05).
Effect of candesartan on the ratio of lumen-wall areas in the middle cerebral artery of spontaneously hypertensive rats
Treatment with candesartan significantly increased the ratio of lumen-wall areas of the medial cerebral artery, by decreasing the wall (inti- Figure 5 Topography of the infarction in spontaneously hypertensive rats after middle cerebral artery occlusion. Table 1 Effect of treatment with candesartan on blood pressure, infarct size and volume of brain oedema in spontaneously hypertensive rats after middle cerebral artery occlusion. 
Vehicle Candesartan
Sections stained with 2,3,5-triphenyltetrazolium chloride (TTC), after two hours of occlusion of the middle cerebral artery with reperfusion, as described in text. Nonischaemic areas had converted TTC to a deep red formazan compound, and appear dark in the figure. Ischaemic areas failed to metabolise TTC and appear white in the figure.
Note the marked decrease in the ischaemic area of the SHR pre-treated with candesartan before middle cerebral artery occlusion. Scale bar is 10 mm.
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Effects of candesartan on cerebrovascular autoregulation of spontaneously hypertensive rats and Wistar-Kyoto rats
Control SHR showed a significant shift to the right, towards higher BPs, when compared with WKY, in the lower part of the autoregulation curve ( Figure  4 ). Treatment with candesartan significantly shifted the lower limits of autoregulation in SHR towards the left, in the direction of lower blood pressures. After treatment for 14 days, the lower limit of autoregulation was no longer significantly different from that of untreated WKY (Figure 4 ).
Effects of temporary occlusion of the middle cerebral artery followed by reperfusion in spontaneously hypertensive rats
In preliminary experiments, we determined that untreated SHR were far more sensitive to ischaemia after middle cerebral artery occlusion than WKY rats. Because of this, and because of the higher incidence of stroke in hypertension, we confined our studies to SHR. Immediately after occlusion of the middle cerebral artery, cortical CBF at the periphery of the ischaemic lesion decreased abruptly to about 15% of baseline values in vehicle-treated SHR, and pre-treatment with candesartan did not alter the initial abrupt decrease in blood flow (results not shown). However, as the period of ischaemia progressed, rats pre-treated with candesartan recovered a significant proportion of the cortical CBF. When measured after 1 hour of ischaemia, the cortical CBF of candesartan-treated SHR was about 25% of baseline values, while the cortical CBF in vehicletreated rats remained at about 15% of baseline values ( Figure 3 ). Ischaemia resulting from middle cerebral artery occlusion resulted in brain injury of the ipsilateral hemisphere including cortical and subcortical (striatum-pallidum) areas, and significant ipsilateral brain oedema. In the candesartan-pre-treated SHR, submitted to 2 hours ischaemia followed by reperfusion, and measured after 24 hours, both the total volume of injury, corrected for oedema, and the volume of brain oedema were significantly decreased relative to those in control, vehicletreated rats (Table 1 and Figure 5 ).
Discussion
The present results confirm our previous findings that chronic pre-treatment with the insurmountable AT 1 -antagonist, candesartan, given peripherally for two weeks to genetically hypertensive rats, normalises the lower end of the cerebrovascular autoregulation and reduces the decrease in CBF during ischaemia, as well as the resulting neuronal injury and brain damage. 21 We have previously shown that chronic candesartan treatment inhibits binding of Ang II to AT 1 -receptors in brain arteries and in the NTS. 21 We now report that this treatment decreases Ang II AT 1 -receptor binding in other brain areas involved in the control of central sympathetic activity and the brain vascular sympathetic tone, such as the PVN. In addition, we now demonstrate that chronic pre-treatment with candesartan significantly increases the ratio of the lumen-wall area in a major cerebral artery, the middle cerebral artery. This is the result of a significant decrease in the area of the media-intima layers, probably due to arterial remodelling as a result of AT 1 -receptor inhibition by candesartan, blocking the growthinducing effects of Ang II.
Hypertensives are pre-disposed to brain ischaemia and stroke because their cerebral arteries are less compliant, with increased thickness and smooth muscle proliferation. 9, 22 This results in a shift of the cerebrovascular autoregulatory curve to the right and a decreased capacity for vasodilatation and cerebrovascular adaptation to the reduction in blood flow during stroke. 10, 11 In normotensive rats, chronic candesartan treatment shifted the autoregulatory curve to the left. 12 This suggested that stimulation of AT 1 -receptors by Ang II results in a normal vasoconstrictor tone in cerebral arteries, and that this tone is probably enhanced in hypertension. Studies on SHR revealed that chronic 12 administration of candesartan also normalises the cerebrovascular autoregulatory curve 12, 23 and the present results support these findings. This is probably due to the decrease in the medial thickness of cerebral arteries, as demonstrated here, which follows inhibition of smooth muscle proliferation, in a manner similar to that of ACE-I. 5, 9, 22, 23 On the other hand, normalisation of the autoregulatory curve by acute administration of candesartan, as reported earlier, 11 is probably mainly a response to the inhibition of the sympathetic tone of cerebral arteries following AT 1 -blockade.
During stroke, if cerebrovascular responses were normalised by AT 1 -receptor blockade, the capacity for vasodilatation in areas receiving collateral circulation could be improved and restored, and blood flow could be more easily maintained or recovered than in control untreated subjects, as evidenced by the decreased volume of ischaemic injury in the cortex of rats pre-treated with candesartan. This occurs probably because of the partial preservation of CBF to the cortex during ischaemia, whereas in non-treated animals, blood flow is reduced to about 15-20% of preischaemia values. 21 The beneficial effect of candesartan may be predominantly the result of remodelling of cerebral arteries, as demonstrated here by the marked increase in the ratio of lumenwall areas in a major cerebral artery. In addition, peripheral administration of candesartan inhibits AT 1 -receptor binding in brain areas such as the NTS and the PVN, contributing to the regulation of cerebrovascular flow through modulation of central sympathetic activity and in turn modulated by the brain Ang II system 12, 23 and in the middle cerebral artery.
In SHR, both the central sympathetic activity and the central Ang II system are activated. 24 
